Depósito Académico >
CIMA (Centro de Investigación Médica Aplicada) >
Área de Oncología >
DA - CIMA - Oncología - Inmunoterapia - Artículos de Revista >
Please use this identifier to cite or link to this item:
|Title: ||Identification of the B-cell tumor-specific molecular fingerprint using non-radiolabelled PCR consensus primers|
|Author(s) : ||Bendandi, M. (Maurizio)|
Tonelli, R. (R.)
Maffei, R. (R.)
Botti, S. (S.)
Turi, C. (C.)
Sartini, R. (R.)
Inoges, S. (Susana)
Calvillo, M.R. (M.R.)
Zinzani, P.L. (P.L.)
Pession, A. (A.)
Pileri, S.A. (S.A.)
Paolucci, G. (G.)
|Issue Date: ||2001|
|Publisher: ||Oxford University Press|
|Citation: ||Bendandi M, Tonelli R, Maffei R, Botti S, Turi C, Sartini R, et al. Identification of the B-cell tumor-specific molecular fingerprint using non-radiolabelled PCR consensus primers. Ann Oncol 2001 Oct;12(10):1479-1484.|
The complementarity determining region 3 (CDR3) of the immunoglobulin (Ig) heavy chain variable region (VH) is the most reliable molecular fingerprint for most if not all human B cells. The nucleotide sequence encoding for any B-cell tumor-specific VH CDR3 is currently identified by PCR sequencing based on procedures involving the usage of either radioactive materials, patient/family-specific primers, or bacterial cloning.
PATIENTS AND METHODS:
In six consecutive patients with follicular lymphoma we assessed the feasibility of a method that allows for identification of the tumor-specific VH CDR3 using consensus primers while avoiding both radioactive materials and bacterial cloning procedures.
The tumor-specific VH CDR3 was successfully identified in all six patients in nearly half the time typically required by any other method currently utilized. The feasibility of the proposed method was not significantly affected either by the tumor-specific Ig isotype, or by the tumor infiltration in the original biopsy specimen. In the three patients for whom tumor specimen-derived hybridomas were available, the tumor-specific VH CDR3 was also found in at least 8 of 10 of them.
The proposed method allows the ability to quickly identify the B-cell tumor-specific VH CDR3 using consensus primers while avoiding radioactive materials and bacterial cloning procedures.|
|Publisher version (URL): ||http://annonc.oxfordjournals.org/content/12/10/1479.long|
|Appears in Collections:||DA - CIMA - Oncología - Inmunoterapia - Artículos de Revista|
DA - CUN - Hematología y Hemoterapia - Artículos de revista
DA - CUN - Área de Terapia Celular - Artículos de revista
DA - Medicina - Hematología - Artículos de revista
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.